Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$95.50 USD

95.50
1,324,649

+1.07 (1.13%)

Updated Aug 7, 2025 04:00 PM ET

Pre-Market: $96.00 +0.50 (0.52%) 8:46 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (142 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Markets Upbeat on Vaccine Efficacy Against Omicron Variant

by Zacks Equity Research

Markets Upbeat on Vaccine Efficacy Against Omicron Variant

Mark Vickery headshot

Remedies for Omicron Apparent, Markets Up Again

by Mark Vickery

New forms of Covid-19 appear to be growing more highly infectious, if not necessarily more life-threatening.

Rimmi Singhi headshot

Don't Squander Your Income on These 3 Toxic Stocks

by Rimmi Singhi

Precisely figuring out toxic stocks and discarding or short selling those at the right time is the key to safeguarding your portfolio from big losses.

Zacks Equity Research

Illumina's (ILMN) New Alliance to Accelerate Genomics in China

by Zacks Equity Research

Illumina's (ILMN) Genomics Incubator will support companies poised to deliver breakthrough applications in genomics and multiomics.

Zacks Equity Research

Illumina (ILMN) iHope Genetic Health Program Expands WGS Access

by Zacks Equity Research

Illumina's (ILMN) launch of iHope Genetic Health program will expand access to WGS to low- and middle-income communities worldwide.

Zacks Equity Research

Should You Invest in the VanEck Biotech ETF (BBH)?

by Zacks Equity Research

Sector ETF report for BBH

Zacks Equity Research

Illumina (ILMN) Q3 Earnings Top Estimates, 2021 Revenue View Up

by Zacks Equity Research

Illumina (ILMN) exited the third quarter with better-than-expected results on strength in Core Illumina and the newly-acquired GRAIL businesses.

Zacks Equity Research

Illumina (ILMN) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Illumina (ILMN) delivered earnings and revenue surprises of 16.94% and 6.63%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

EXEL vs. ILMN: Which Stock Is the Better Value Option?

by Zacks Equity Research

EXEL vs. ILMN: Which Stock Is the Better Value Option?

Daniel Laboe headshot

Will Christmas Come Early For Investors This Year?

by Daniel Laboe

Welcome to November, the seasonally strongest month for S&P 500 returns, averaging growth of 2.5% over the past decade

Zacks Equity Research

Illumina (ILMN) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Zacks.com featured highlights include: Stoneridge, Illumina, TPI Composites and JD.com

by Zacks Equity Research

Zacks.com featured highlights include: Stoneridge, Illumina, TPI Composites and JD.com

Rimmi Singhi headshot

Let Go of These 4 Toxic Stocks Right Away

by Rimmi Singhi

Steer clear of toxic stocks like SRI, ILMN, TPIC and JD to safeguard your portfolio from losses.

Zacks Equity Research

New Strong Sell Stocks for October 19th

by Zacks Equity Research

ACCD, EAT, ILMN, MAXN, and TM have been added to the Zacks Rank #5 (Strong Sell) List on October 19, 2021

Zacks Equity Research

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Zacks Equity Research

Here's Why You Should Hold on to Illumina (ILMN) for Now

by Zacks Equity Research

Investors are optimistic about Illumina (ILMN) owing to its strategic partnerships and wider market adoption of its products.

Daniel Laboe headshot

Market Bears Take The Bulls By The Horns As Q4 Kicks Off

by Daniel Laboe

We are not out of the correction woods yet as mega-cap tech breaks below Friday's lows

Zacks Equity Research

Illumina (ILMN) Oncology Growth Aids Amid GRAIL Merger Hurdle

by Zacks Equity Research

Illumina (ILMN) is making progress outside the United States to ensure all expecting families have access to NIPT.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Eli Lilly, Costco, Applied Materials, Illumina and Norfolk Southern Corp

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Eli Lilly, Costco, Applied Materials, Illumina and Norfolk Southern Corp

Sheraz Mian headshot

Top Stock Reports for Eli Lilly, Costco & Applied Materials

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Costco Wholesale Corporation (COST), and Applied Materials, Inc. (AMAT).

Zacks Equity Research

QGEN or ILMN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

QGEN vs. ILMN: Which Stock Is the Better Value Option?

Zacks Equity Research

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Zacks Equity Research

Illumina (ILMN), Merck Ink Cancer Companion Diagnostics Deal

by Zacks Equity Research

Illumina (ILMN) collaborated with Merck to develop and commercialize companion diagnostics to identify ovarian cancer patients with positive HRD status for treatment with LYNPARZA.

Zacks Equity Research

Illumina (ILMN), Grail Merger Sees Futher Regulatory Challenges

by Zacks Equity Research

According to Illumina (ILMN), GRAIL will continue to operate as a separate company until the ongoing regulatory review by the EC is completed.

Zacks Equity Research

Illumina (ILMN) Shares Slip on GRAIL Buyout Deal Completion

by Zacks Equity Research

Illumina (ILMN) acquisition of GRAIL will expand patient access to life-saving multi-cancer early-detection test.